Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer

Lancet

Volumn 360, Issue 9334, 2002, Pages 683-689

  Klein, Christoph A ^a   Blankenstein, Thomas J F ^a   Schmidt Kittler, Oleg ^a   Petronio, Marco ^a   Polzer, Bernhard ^a   Stoecklein, Nikolas H ^a,b   Riethmüller, Gert ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ALGORITHM; ARTICLE; BLOOD ANALYSIS; BONE MARROW; BREAST CANCER; CANCER SCREENING; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DNA HYBRIDIZATION; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC ORGANIZATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMMUNOCYTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; METASTASIS; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; SEQUENCE ANALYSIS; TUMOR CELL;

EID: 0037206022     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)09838-0     Document Type: Article

References (33)

1. Fujii H., Marsh C., Cairns P., Sidransky D., Gabrielson E. Genetic divergence in the clonal evolution of breast cancer. Cancer Res. 56:1996;1493-1497.
2. Gorunova L., Hoglund M., Andren-Sandberg A., et al. Cytogenetic analysis of pancreatic carcinomas: intratumor heterogeneity and nonrandom pattern of chromosome aberrations. Genes Chromosomes Cancer. 23:1998;81-99.
3. Heim S., Teixeira M.R., Dietrich C.U., Pandis N. Cytogenetic polyclonality in tumors of the breast. Cancer Genet Cytogenet. 95:1997;16-19.
4. Macintosh C.A., Stower M., Reid N., Maitland N.J. Precise micro dissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res. 58:1998;23-28.
5. Mirchandani D., Zheng J., Miller G.J., et al. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol. 147:1995;92-101.
6. Pandis N., Teixeira M.R., Adeyinka A., et al. Cytogenetic comparison of primary tumors and lymph node metastases in breast cancer patients. Genes Chromosomes Cancer. 22:1998;122-129.
7. Harris D.T. Introduction: the evolution of early systemic therapy. Semin Oncol. 28:2001;1-2.
8. Chay C., Smith D.C. Adjuvant and neoadjuvant therapy in prostate cancer. Semin Oncol. 28:2001;3-12.
9. Gianni L., Valagussa P., Zambetti M., Moliterni A., Capri G., Bonadonna G. Adjuvant and neoadjuvant treatment of breast cancer. Semin Oncol. 28:2001;13-29.
10. Macdonald J.S., Astrow A.B. Adjuvant therapy of colon cancer. Semin Oncol. 28:2001;30-40.
11. Edwards B.K., Howe H.L., Ries L.A., et al. Annual report to the nation on the status of cancer, -1999, featuring implications of age and aging on US cancer burden. Cancer ; 94. 2002:1973;2766-2792.
12. Schlimok G., Funke I., Holzmann B., et al. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci USA. 84:1987;8672-8676.
13. Passlick B., Izbicki J.R., Kubuschok B., et al. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. J Clin Oncol. 12:1994;1827-1832.
14. Pantel K., Cote R.J., Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst. 91:1999;1113-1124.
15. Lindemann F., Schlimok G., Dirschedl P., Witte J., Riethmuller G. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet. 340:1992;685-689.
16. Jauch K.-W., Heiss M.M., Gruetzner U., et al. Prognostic significance of bone marrow micrometastasis in patients with gastric cancer. J Clin Oncol. 14:1996;1810-1817.
17. Pantel K., Izbicki J., Passlick B., et al. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet. 347:1996;649-653.
18. Izbicki J.R., Hosch S.B., Pichlmeier U., et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med. 337:1997;1188-1194.
19. Thorban S., Rosenberg R., Busch R., Roder R.J. Epithelial cells in bone marrow of oesophageal cancer patients: a significant prognostic factor in multivariate analysis. Br J Cancer. 83:2000;35-39.
20. Braun S., Pantel K., Müller P., et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med. 342:2000;525-533.
21. Weckermann D., Muller P., Wawroschek F., Harzmann R., Riethmüller G., Schlimok G. Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value. J Urol. 166:2001;699-703.
22. Klein C.A. The biology and analysis of single disseminated tumour cells. Trends Cell Biol. 10:2000;489-493.
23. Braun S., Kentenich C., Janni W., et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol. 18:2000;80-86.
24. Klein C.A., Schmidt Kittler O., Schardt J.A., Pantel K., Speicher M.R., Riethmüller G. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci USA. 96:1999;4494-4499.
25. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
26. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 19:2002;607-614.
27. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 95:1998;14863-14868.
28. Kallioniemi A., Kallioniemi O.P., Sudar D., et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science. 258:1992;818-821.
29. Gualberto A., Aldape K., Kozakiewicz K., Tlsty T.D. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci USA. 95:1998;5166-5171.
30. Stapleton A.M., Timme T.L., Gousse A.E., et al. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res. 3:1997;1389-1397.
31. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 3:2002;415-428.
32. Loeb L.A. A mutator phenotype in cancer. Cancer Res. 61:2001;3230-3239.
33. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instabilities in human cancers. Nature. 396:1998;643-649.